A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This is a single center, open phase I dose escalation study. This study will assess the
highest tolerable intratumoral dose of ipilimumab (Yervoy) in combination with IL-2
(Proleukin) in patients with unresectable stages III-IV melanoma with accessible cutaneous,
subcutaneous, and/or nodal lesions. The objective is to primarily assess the safety of the
drug combination, and to secondarily obtain preliminary data on the clinical efficacy of the
combination.